FDA panel votes 15-1-1 that Abbott's (ABT) Humira benefit is meaningful

August 28, 2012 2:18 PM EDT Send to a Friend
FDA panel votes 15-1-1 that Abbott's (NYSE: ABT) Humira benefit is meaningful. The panel also said Humira has benefit in UC after 8 weeks.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

FDA, General News

Add Your Comment